IJE Advance Access originally published online on March 11, 2005
International Journal of Epidemiology 2005 34(3):575-576; doi:10.1093/ije/dyi009
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press on behalf of the International Epidemiological Association © The Author 2005; all rights reserved.
Commentary |
Commentary: Pneumococcal immunization may not be cost-effective in the elderly in developed countries
Department of Public Health, University of Aberdeen, Medical School Buildings, Foresterhill, Aberdeen AB25 2ZD, Scotland, UK. E-mail: n.r.waugh@abdn.ac.uk
| The first 10% of the full text of this article appears below. |
Mangtani and colleagues1 have created a model to examine whether pneumococcal immunization in people >64 years in a developed country setting is cost-effective. The key elements in any such programme would be: effectiveness in preventing pneumococcal disease; the frequency of such events; the costs of the immunization programmevaccine cost and payments to general practices (or others)the costs avoided from reduction of disease and hence of events such as hospital admissions; and the net balance of costs and benefits. In their model, data on some of these elements are more certain than